SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GUMM - Eliminate the Common Cold
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mad2 who wrote (4022)12/2/2001 1:56:13 PM
From: DanZ  Read Replies (1) of 5582
 
<Anyway looks like GUMM is yet overvalued and simply a dead stock.>

On what basis do you assert that GUMM is overvalued? It's easy to type a line of BS, but how about providing some muscle behind it. GUMM is valued at about twice their cash and they have no debt. The interest on their cash balance alone is sufficient to cover all their overhead expenses since they shed the gum business. Come on, Mad, tell me how GUMM is overvalued. What a joke. Mike already replied to your other BS so I'll leave it at that.

A dead stock? Yes, but dead stocks can come back to life when you least expect it. Given the low valuation relative to the assets, high short interest although it has declined three months in a row, odds that at least the next two quarters will be profitable, and the fact that Gum Tech is pursuing a new partner for their nicotine gum products, make it is much more likely that the stock will move up from here than down.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News